Jackson ImmunoResearch Launches Secondary Antibodies for VHH Discovery
Image credit: Jackson ImmunoResearch
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Jackson ImmunoResearch, manufacturer of secondary antibodies for the life science market, announces a new range of products for scientists developing single-domain VHH antibodies.
The new Anti-Alpaca secondary antibody product line targets the IgG repertoire of camelid immunoglobulins, including whole molecule, subclass and VHH domain specificities. They are raised against alpaca and cross-react with llama.
Anti-Alpaca IgG subclasses 2+3 specific antibodies enable scientists to monitor immune response and pinpoint the optimal B cell harvest timeframe. Anti-Alpaca VHH domain antibodies were also developed to detect single-domain antibodies across all immunotechniques and will be an indispensable tool in diagnostics and drug development.
David A. Fancy PhD, chief operating officer, commented “Jackson ImmunoResearch is very excited to bring anti-camelid secondary antibodies to the marketplace. The single-domain antibody market is rapidly expanding. These antibodies are 1/10th the size of canonical immunoglobulins making them ideal for drug delivery and super-resolution imaging, among many other potential uses. Secondary antibodies for VHH discovery are designed to support research needs, reduce project time and improve success rates.”
The new Anti-Alpaca secondary antibody product line targets the IgG repertoire of camelid immunoglobulins, including whole molecule, subclass and VHH domain specificities. They are raised against alpaca and cross-react with llama.
Anti-Alpaca IgG subclasses 2+3 specific antibodies enable scientists to monitor immune response and pinpoint the optimal B cell harvest timeframe. Anti-Alpaca VHH domain antibodies were also developed to detect single-domain antibodies across all immunotechniques and will be an indispensable tool in diagnostics and drug development.
David A. Fancy PhD, chief operating officer, commented “Jackson ImmunoResearch is very excited to bring anti-camelid secondary antibodies to the marketplace. The single-domain antibody market is rapidly expanding. These antibodies are 1/10th the size of canonical immunoglobulins making them ideal for drug delivery and super-resolution imaging, among many other potential uses. Secondary antibodies for VHH discovery are designed to support research needs, reduce project time and improve success rates.”
